Active	Status	Sponsor type	Region	Phase	Filter
1 Active 3 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
contraloid (PRI-002) / Priavoid
PRImus-AD, NCT06182085: Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)	Active, not recruiting	2	270	Europe, RoW	PRI-002, Contraloid, Placebo	PRInnovation GmbH, Priavoid, Federal Agency for Disruptive Innovation - SPRIN-D, Julius Clinical	Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset	04/26	04/26
PRI-500 / Priavoid
No trials found
PRI-003 / Priavoid
No trials found
PRI-200 / Priavoid
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
contraloid (PRI-002) / Priavoid
PRImus-AD, NCT06182085: Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)	Active, not recruiting	2	270	Europe, RoW	PRI-002, Contraloid, Placebo	PRInnovation GmbH, Priavoid, Federal Agency for Disruptive Innovation - SPRIN-D, Julius Clinical	Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset	04/26	04/26
PRI-500 / Priavoid
No trials found
PRI-003 / Priavoid
No trials found
PRI-200 / Priavoid
No trials found